Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE II-2Lipodystrophies : prévalence, présentations cliniques et facteurs associésird-00718213, version 1 - 16 Jul 201215. Mercier S, Ngom Gueye NF, Cournil A, Fontbonne A, Copin N,Ndiaye I, et al. Lipodystrophy and metabolic disorders in HIV-1-infectedadults on 4-to-9-year antiretroviral therapy in Senegal: acase-control study. J Acquir Immune Defic Syndr 2009 ; 51:224–23016. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D,Bashi J, Akakpo J, et al. Incidence of lipodystrophy and metabolicdisorders in patients starting non-nucleoside reverse transcriptaseinhibitors in Benin. Antiviral Therapy 2009, 14:371-380.17. Mutimura E., Stewart A., Rheeder P., Crowther N.J. MetabolicFunction and the prevalence of lipodystrophy in a population ofHIV-infected African subjects receiving Highly Active AntiretroviralTherapy. J Acquir Immune Defic Syndr, 2007, 46 : 451-455.18. Van Griensven J., De Naeyer L., Mushi T., Ubarijoro S.,Gashumba D., Gazille C., Zachariah R. High prevalence oflipoatrophy among patients on stavudine-containing first-lineantiretroviral therapy regimens in Rwanda. Transactions of theRoyal Society of Tropical Medecine and Hygiene, 2007, 101 :793-798.19. Eholié SP, Lacombe K, Krain A, Ouiminga M, Diallo Z,Bouchaud O, et al. Incidence des lipodystrophies, des anomaliesmétaboliques et évaluation du risque CV dans une cohorte depatients originaires d’Afrique subsaharienne sous multithérapieantirétrovirale. Disponible à partir de : URL :http://www.imea.fr/imea-rencontresNS/RNS10-Diaporamas.php(Consulté le 12/02/2011).20. Gervasoni C., Ridolfo A.L., Trifiro G., Santambrogio S.,Norbiato G., Musicco M., et al. Redistribution of body fat in HIV-infectedwomen undergoing combined antiretroviral therapy. AIDS,1999, 13 : 465-471.21. Galli M., Veglia F., Angarano G., Santambrogio S., MeneghiniE., Gritti F., et al. Gender differences in antiretroviral drug-relatedAdipose Tissue Alterations. J Acquir Immune Defic Syndr, 2003, 34: 58-61.22. Mothe B, Perez I, Domingo P, Podzamczer D, Ribera E, CurranA, et al. HIV-1 infection in subjects older than 70: a multicentercross-sectional assessment in Catalonia, Spain. Curr HIV Res.2009 Nov;7(6):597-600.23. Nguyen A., Calmy A., Schiffer V., Bernasconi E., Battegay M.,Opravil M., et al. Lipodystrophy and weight changes: data from theSwiss HIV Cohort Study, 2000-2006 HIV Med. 2008 ; 9 : 142-150.24. Thiébaut R, Daucourt V, Mercié P, Ekouévi DK, Malvy D, MorlatP, et al. Lipodystrophy, metabolic disorders, and human immunodeficiencyvirus infection: Aquitaine Cohort, France, 1999. Grouped'Epidémiologie Clinique du Syndrome d'ImmunodéficienceAcquise en Aquitaine. Clin Infect Dis. 2000 Dec;31(6):1482-7.25. Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C. Intervirology.2010;53(4):240-6. Epub 2010 Mar 30. Evaluation of a6-year highly active antiretroviral therapy in Chinese HIV-1-infectedpatients.26. Zhang L, Li M, Tao MM, Qiu ZF, Xie J, Han Y, et al. [A study ofHIV-related lipodystrophy syndrome in 55 HIV-infected Chineseadult patients]. Zhonghua Nei Ke Za Zhi. 2009 Feb;48(2):118-21.27. Monnerat BZ, Cerutti Junior C, Caniçali SC, Motta TR.Clinical and biochemical evaluation of HIV-related lipodystrophy inan ambulatory population from the Hospital UniversitárioCassiano Antonio de Morais, Vitória, ES, Brazil. Braz J Infect Dis.2008 Aug;12(4):364-8.28. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P,Krudsood S, PitisuttithumP. The efficacy and adverse effects of GPO-VIR(stavudine+lamivudine+nevirapine) in treatment-naïve adult HIVpatients. Southeast Asian J Trop Med Public Health. 2005Mar;36(2):362-9.29. Lichtenstein K.A., Ward D.J., Moorman A.C., Delaney K.M.,Young B., Palella F.J. et al. and the HIV Outpatients Study Investigators.Clinical assessment of HIV-associated lipodystrophy in anambulatory population. AIDS, 2001, 15 : 1389-1398.30. Saves M., Raffi F., Capeau J., Rozenbaum W., Ragnaud J.M.,Perronne C., et al. Factors related to lipodystrophy and metabolicalterations in patients with human immunodeficiency virus infectionreceiving highly active antiretroviral therapy. Clin. Infect. Dis. 2002; 34 : 1396-1405.31. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, AboulkerJP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infectedpatients: results of a substudy from a comparative trial.AIDS. 2002 Dec 6;16(18):2447-54.32. George JA, Venter WDF, Van Deventer HE, Crowther NJ. Alongitudinal study of the changes in body fat and metabolicparameters in a South African population of HIV-positive patientsreceiving an antiretroviral therapeutic regimen containingstavudine. AIDS Res. Hum. Retroviruses. 2009 août;25(8):771-781.33. Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez MdelM, Mateo MG, et al. Relationship between HIV/Highly active antiretroviraltherapy (HAART)-associated lipodystrophy syndrome andstavudine-triphosphate intracellular levels in patients with stavudine-basedantiretroviral regimens. Clin Infect Dis. 2010 Apr1;50(7):1033-40.34. Cournil A, Coudray M, Kouanfack C, Essomba CN, TonfackCA, Biwolé-Sida M, et al. Reduced dose of stavudine and lipoatrophyin HIV-infected patients in Cameroon. Antivir Ther.2010;15(7):1039-43.35. Howard A.A., Lo Y., Floris-Moore M., Klein R.S., Fleischer N.,Schoenbaum E.E. Hepatitis C virus infection is associated withinsulin resistance among older adults with or at risk of HIV infectionAIDS 2007 ; 21 : 633-641.36. Mehta S.H., Moore R.D., Thomas D.L., Chaisson R.E.,Sulkowski M.S. The effect of HAART and HCV infection on thedevelopment of hyperglycemia among HIV-infected persons J.Acquir. Immune Defic. Syndr. 2003 ; 33 : 577-584.37. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, LangeJM, Reiss P. Stavudine but not didanosine as part of HAARTcontributes to peripheral lipoatrophy: a substudy from the AntiretroviralRegimen Evaluation Study (ARES). HIV Clin Trials. 2007Sep-Oct;8(5):337-44.38. Van Griensven J, Zachariah R, Rasschaert F, Mugabo J,Atté EF, Reid T. Stavudine- and nevirapine-related drug toxicitywhile on generic fixed-dose antiretroviral treatment: incidence,timing and risk factors in a three-year cohort in Kigali, Rwanda.Trans. R. Soc. Trop. Med. Hyg. 2010 févr;104(2):148-153.39. Wunder DM, Fux CA, Bersinger NA, Mueller NJ, Hirschel B,Cavassini M, et al; Swiss HIV Cohort Study. Androgen andgonadotropin patterns differ in HIV-1-infected men who developlipoatrophy during antiretroviral therapy: a case-control study. HIVMed. 2008 Jul;9(6):427-32.75